טוען...
Astragaloside IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats
BACKGROUND: Astragaloside IV (AS-IV) was reported to play a role in improving diabetic nephropathy (DN), however, the underlying mechanisms still remain unclear. The aim of the present study is to investigate whether AS-IV ameliorates DN via the regulation of endothelial nitric oxide synthase (eNOS)...
שמור ב:
| הוצא לאור ב: | BMC Complement Altern Med |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6896771/ https://ncbi.nlm.nih.gov/pubmed/31805910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12906-019-2728-9 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|